Literature DB >> 19519490

Farnesyltransferase inhibitor as anticancer agent.

Anuj G Agrawal1, Rakesh R Somani.   

Abstract

Ras protein plays pivotal roles in control of normal and transformed cell growth. These ras genes are mutated in 30% of human cancer. For functioning of Ras protein its prenylation (farnesylation) is required. Therefore targeting Ras farnesylation is valuable approach for cancer treatment. Farnesyltransferase inhibitor (FTI) has been developed as anticancer drug and is currently evaluated in clinical trials. Different types of FTI have been identified that inhibit Ras farnesylation. FTI in combination with some cytotoxic antineoplastic drugs, exhibit additive effects.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19519490     DOI： 10.2174/138955709788452702

Source DB:  PubMed          Journal:  Mini Rev Med Chem        ISSN： 1389-5575            Impact factor:   3.862


  18 in total

Review 1.  Protein farnesylation and disease.

Authors:  Giuseppe Novelli; Maria Rosaria D'Apice
Journal:  J Inherit Metab Dis       Date:  2012-02-04       Impact factor: 4.982

Review 2.  Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma.

Authors:  Roberto E Favoni; Antonio Daga; Paolo Malatesta; Tullio Florio
Journal:  Br J Pharmacol       Date:  2012-05       Impact factor: 8.739

3.  Molecular dynamics analysis of a series of 22 potential farnesyltransferase substrates containing a CaaX-motif.

Authors:  Sérgio F Sousa; João T S Coimbra; Diogo Paramos; Rita Pinto; Rodrigo S Guimarães; Vitor Teixeira; Pedro A Fernandes; Maria J Ramos
Journal:  J Mol Model       Date:  2012-09-26       Impact factor: 1.810

4.  Trinuclear Metal Clusters in Catalysis by Terpenoid Synthases.

Authors:  Julie A Aaron; David W Christianson
Journal:  Pure Appl Chem       Date:  2010       Impact factor: 2.453

5.  Farnesyltransferase inhibitor FTI-277 inhibits PD-L1 expression on septic spleen lymphocytes and promotes spleen lymphocyte activation.

Authors:  W Li; J Tu; X Liu; W Yang
Journal:  Clin Exp Immunol       Date:  2017-07-14       Impact factor: 4.330

Review 6.  Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.

Authors:  Pearlie K Epling-Burnette; Thomas P Loughran
Journal:  Expert Opin Investig Drugs       Date:  2010-05       Impact factor: 6.206

Review 7.  Membrane Dynamics in Health and Disease: Impact on Cellular Signalling.

Authors:  Pranav Adhyapak; Shobhna Kapoor
Journal:  J Membr Biol       Date:  2019-08-21       Impact factor: 1.843

8.  Polyisoprenylated Cysteinyl Amide Inhibitors Deplete K-Ras and Induce Caspase-dependent Apoptosis in Lung Cancer Cells.

Authors:  Augustine T Nkembo; Felix Amissah; Elizabeth Ntantie; Rosemary A Poku; Olufisayo O Salako; Offiong Francis Ikpatt; Nazarius S Lamango
Journal:  Curr Cancer Drug Targets       Date:  2019       Impact factor: 3.428

9.  Evaluation of prenylated peptides for use in cellular imaging and biochemical analysis.

Authors:  Joshua D Ochocki; Urule Igbavboa; W Gibson Wood; Edgar A Arriaga; Elizabeth V Wattenberg; Mark D Distefano
Journal:  Methods Mol Biol       Date:  2014

10.  Polyisoprenylated methylated protein methyl esterase overexpression and hyperactivity promotes lung cancer progression.

Authors:  Felix Amissah; Randolph Duverna; Byron J Aguilar; Rosemary A Poku; Gebre-Egziabher Kiros; Nazarius S Lamango
Journal:  Am J Cancer Res       Date:  2014-03-01       Impact factor: 6.166
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.